Medline Industries, Inc., a leading global manufacturer and distributor of healthcare supplies, is headquartered in the United States. Founded in 1910, the company has established a strong presence in North America and beyond, serving hospitals, nursing homes, and other healthcare facilities. Medline is renowned for its extensive range of products, including surgical instruments, medical apparel, and infection prevention solutions, all designed to enhance patient care and operational efficiency. With a commitment to innovation, Medline has achieved significant milestones, such as expanding its product lines and investing in advanced manufacturing technologies. The company holds a prominent market position, recognised for its quality and reliability, making it a trusted partner in the healthcare industry. Medline's dedication to customer service and tailored solutions further distinguishes it in a competitive landscape.
How does Medline Industries's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Medline Industries's score of 41 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Medline Industries reported total carbon emissions of approximately 7,278,301,000 kg CO2e globally. This figure includes 173,837,000 kg CO2e from Scope 1 emissions, 131,904,000 kg CO2e from Scope 2 emissions (with 131,009,418 kg CO2e attributed to purchased electricity), and a significant 6,972,560,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (5,677,074,780 kg CO2e) and upstream transportation and distribution (400,306,555 kg CO2e). In the UK, Medline's emissions for 2023 totalled approximately 484,250 kg CO2e, with Scope 1 emissions at 1,330 kg CO2e, Scope 2 emissions at 11,310 kg CO2e, and Scope 3 emissions at 471,610 kg CO2e. Medline Industries has set ambitious climate commitments, aiming for a 30% reduction in Scope 1 and Scope 2 emissions from a 2023 baseline by 2030. Additionally, they are committed to achieving Net Zero emissions by 2050, with projections indicating a 42% reduction in total Scope 1 and Scope 2 emissions by 2030, targeting a reduction to 63 tCO2e. For Scope 3 emissions, they aim for a 25% reduction, projecting a decrease to 513 tCO2e by 2030. These commitments reflect Medline's proactive approach to addressing climate change and reducing its carbon footprint across all scopes of emissions.
Access structured emissions data, company-specific emission factors, and source documents
2016 | 2019 | 2020 | 2021 | 2023 | |
---|---|---|---|---|---|
Scope 1 | 45,201,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
Scope 2 | 81,309,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
Scope 3 | 90,611,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medline Industries is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.